X4 Pharmaceuticals, Inc. (XFOR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 58/100 (HIGH), 18.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.35% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
- X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
- X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates
- X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for X4 Pharmaceuticals, Inc..
Full XFOR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.